The Usefulness of Inspiratory Flow Rate during Inhalation Corticosteroid Therapy in Asthma

被引:3
|
作者
Banno, Masashi [2 ]
Ibata, Hidenori
Niimi, Takashi [1 ]
Sato, Shigeki [3 ]
Matsushita, Ryo [4 ]
机构
[1] Nagoya Cent Hosp, Dept Resp Med, Nakamura Ku, Aichi 4530801, Japan
[2] Nagoya Cent Hosp, Dept Pharmacol, Aichi 4530801, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Aichi, Japan
[4] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
Peak inspiratory flow rate; In-Check device; Inhalation therapy; DRY POWDER INHALERS; HYDROFLUOROALKANE-BECLOMETHASONE DIPROPIONATE; DIPROPRIONATE EXTRAFINE AEROSOL; CHECK DIAL DEVICE; CLINICAL-EXPERIENCE; CHILDREN; DISKUS; TURBUHALER; EFFICACY; SAFETY;
D O I
10.1159/000220097
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The recently released handheld In-Check device can be used to measure the peak inspiratory flow rate (PIF) of patients and is reportedly useful in determining whether the PIF is sufficient for using inhaler devices. In this study, we evaluated the effects of instructions for the use of the device and of the device type based on measurements of the PIF in asthma. Objectives: One hundred and thirty-five asthmatic patients who used a fluticasone propionate Diskus (FP-DK) or a budesonide Turbuhaler (BUD-TH) were studied. Methods: The PIF was measured by the In-Check device. For patients without a sufficient PIF of 50 l/min, instructions for the use of the device were given, and the device was changed to hydrofluoroalkan-beclomethasone dipropionate (HFA-BDP). Results: A significant correlation between the PIF and peak expiratory flow rate (p < 0.0001) was found. In 10 patients in whom the PIF did not increase to 1 50 l/min after instructions, the device was changed to HFA-BDP, which resulted in significant improvements in lung function in terms of the forced expiratory volume in 1 s (p = 0.018), peak expiratory flow (p = 0.038) and the maximum expiratory flow rates at 50% (p = 0.018) and 25% (p = 0.011). Conclusions: Measurement of the PIF by the In-Check device is useful in the clinical management of asthma, to provide an appropriate device so as to improve lung function. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:387 / 392
页数:6
相关论文
共 50 条
  • [21] DANGER IN CORTICOSTEROID THERAPY IN ASTHMA
    不详
    BRITISH MEDICAL JOURNAL, 1965, 2 (5470): : 1108 - +
  • [22] CORTICOSTEROID THERAPY IN CHRONIC ASTHMA
    NASH, J
    JACOMB, RG
    PRACTITIONER, 1968, 201 (1202) : 358 - &
  • [23] CORTICOSTEROID THERAPY IN CHILDHOOD ASTHMA
    TOLLACKSON, KA
    CALIFORNIA MEDICINE, 1965, 103 (02): : 117 - +
  • [24] CONTINUOUS CORTICOSTEROID THERAPY IN ASTHMA
    WINKENWERDER, WL
    GAY, LN
    JOURNAL OF ALLERGY, 1959, 30 (03): : 283 - 283
  • [25] CORTICOSTEROID-THERAPY IN ASTHMA
    DUNLAP, NE
    FULMER, JD
    CLINICS IN CHEST MEDICINE, 1984, 5 (04) : 669 - 683
  • [26] Corticosteroid therapy for acute asthma
    Rowe, BH
    Edmonds, ML
    Spooner, CH
    Diner, B
    Camargo, CA
    RESPIRATORY MEDICINE, 2004, 98 (04) : 275 - 284
  • [27] CORTICOSTEROID-THERAPY IN ASTHMA
    ROGER, M
    GAZETTE MEDICALE DE FRANCE, 1981, 88 (33): : 4609 - &
  • [28] System of inhalation in asthma therapy
    Dubus, JC
    Andrieu, V
    Reynier, JP
    REVUE DES MALADIES RESPIRATOIRES, 2002, 19 (01) : 90 - 92
  • [29] Alcohol inhalation in asthma therapy
    Wossner, R
    Sybrecht, GW
    INTERNIST, 1998, 39 (10): : 1077 - 1078
  • [30] INHALATION-THERAPY OF ASTHMA
    DEBLIC, J
    SCHEINMANN, P
    ARCHIVES FRANCAISES DE PEDIATRIE, 1990, 47 (07): : 487 - 489